---
schema_version: "secwatch.filing_event.v1"
accession: "0001404644-24-000054"
form_type: "8-K"
ticker: "NGNE"
cik: "0001404644"
company_name: "Neurogene Inc."
filed_at: "2024-05-10T23:59:59+00:00"
generated_at: "2026-06-02T03:30:06.348152+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Neurogene Q1 net loss $16.9M; NGN-401 safety positive, on track for efficacy data 4Q24

## Summary
- Cash and investments $169.5M as of March 31, 2024; cash runway into 2H 2026.
- R&D expenses $13.5M (up 31% YoY); net loss $16.9M vs $12.3M in Q1 2023.
- NGN-401 gene therapy for Rett syndrome well-tolerated; all AEs mild/Grade 1.
- Australian regulatory clearance received; interim efficacy data from Cohort 1 expected 4Q 2024.
- Advancing early-stage pipeline; another product candidate expected to enter clinic in 2025.

## SEC filing metadata
- accession: 0001404644-24-000054
- form_type: 8-K
- ticker: NGNE
- cik: 0001404644
- company_name: Neurogene Inc.
- filed_at: 2024-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1404644/000140464424000054/0001404644-24-000054-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1404644/000140464424000054/ngne-20240510.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001404644-24-000054
- JSON: https://secwatch.observer/filing/0001404644-24-000054.json
- Plain text: https://secwatch.observer/filing/0001404644-24-000054.txt

## Key facts
- Earnings Releases
  Neurogene Inc. reported financial results for the quarter ended March 31, 2024.
  - Period: the quarter ended March 31, 2024
  - Result: reported results
  source text: On May 10, 2024, Neurogene Inc. (the “Company”) issued a press release announcing financial results for the quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1404644/000140464424000054/0001404644-24-000054-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.